The guy who tanked Valeant has 'significantly' reduced his short position in the company
Citron Research's Andrew Left has "significantly" reduced his short position in Valeant Pharmaceuticals.
"Think about risk reward here," Left said in an interview with CNBC's Scott Wapner on Tuesday.
It was Citron's report comparing Valeant to infamous accounting fraud Enron that started the company's precipitous stock slide last month.
In the report, Citron alleged that Valeant had been using its relationship with Philidor - a specialty pharmacy that used to distribute Valeant products almost exclusively - to file fake invoices and make its revenue appear greater than it is.
Valeant also purchased the option to buy Philidor for $100 million last December.
When Left's report went live Valeant's share price was at $142. On Tuesday it was at $85 - a 43% drop.
Also since then, Valeant has severed ties with Philidor and announced that the pharmacy will be closed by the end of January 2016.
So Left has to feel like a lot of his work is done.
- Seeking nominations for the 2024 rising stars of adtech
- Eli Lilly stock will surge 29% over the next year with its weight-loss drug on pace to do $60 billion in sales by 2030, BofA says
- A millennial who quit her office job to live in a school bus explains what her lifestyle costs and how she makes 6 figures freelancing
- Mukka Proteins IPO allotment – How to check allotment, GMP, listing date and more
- Know what are the 7 signs and symptoms of high cholesterol in your body
- Tata Motors to demerge biz into two separate listed companies
- Best drinks for constipation relief and digestive ease
- 10 Reasons why you should opt for plant-based diet